Fennec Pharmaceuticals Inc. (FENC) DCF Valuation

Valoración de DCF de Fennec Pharmaceuticals Inc. (Fenc)

US | Healthcare | Biotechnology | NASDAQ
Fennec Pharmaceuticals Inc. (FENC) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Fennec Pharmaceuticals Inc. (FENC) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Como inversionista o analista, la calculadora DCF de Fennec Pharmaceuticals Inc. (FENC) es su recurso de referencia para una valoración precisa. Está equipado con datos reales de Fennec Pharmaceuticals Inc., lo que le permite ajustar los pronósticos y observar los efectos en tiempo real.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .2 .0 1.5 21.3 21.3 21.3 21.3 21.3 21.3
Revenue Growth, % 0 0 -100 0 1284.5 0 0 0 0 0
EBITDA .2 -17.9 -.1 -22.6 -12.4 -2.5 -2.5 -2.5 -2.5 -2.5
EBITDA, % 100 -10520.59 100 -1471.47 -58.18 -11.64 -11.64 -11.64 -11.64 -11.64
Depreciation 13.0 .4 17.2 .1 .3 13.2 13.2 13.2 13.2 13.2
Depreciation, % 100 236.47 100 9.71 1.35 62.21 62.21 62.21 62.21 62.21
EBIT -12.8 -18.3 -17.3 -22.7 -12.7 -2.5 -2.5 -2.5 -2.5 -2.5
EBIT, % 100 -10757.06 100 -1481.17 -59.53 -11.91 -11.91 -11.91 -11.91 -11.91
Total Cash 13.7 30.3 21.1 23.8 13.3 19.7 19.7 19.7 19.7 19.7
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 1.5 8.8
Account Receivables, % 100 0 100 100.65 41.47
Inventories .0 .0 .0 .6 2.2 10.5 10.5 10.5 10.5 10.5
Inventories, % 100 0 100 37.52 10.14 49.53 49.53 49.53 49.53 49.53
Accounts Payable 1.6 1.6 .8 2.4 3.8 17.8 17.8 17.8 17.8 17.8
Accounts Payable, % 100 924.12 100 155.7 17.78 83.56 83.56 83.56 83.56 83.56
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 0 100 0 0.000012925306 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -12.5 -18.1 -17.5 -23.8 -12.7 -2.5 -2.5 -2.5 -2.5 -2.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 2.2 -17.7 -1.0 -24.2 -19.8 10.6 10.7 10.7 10.7 10.7
WACC, % 6.5 6.52 6.54 6.54 6.54 6.53 6.53 6.53 6.53 6.53
PV UFCF
SUM PV UFCF 44.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 11
Terminal Value 241
Present Terminal Value 176
Enterprise Value 220
Net Debt 18
Equity Value 203
Diluted Shares Outstanding, MM 27
Equity Value Per Share 7.62

What You Will Get

  • Real FENC Financial Data: Pre-filled with Fennec Pharmaceuticals' historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Fennec Pharmaceuticals' intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Customizable Forecast Inputs: Adjust essential parameters such as revenue growth, EBITDA %, and R&D expenditures.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other financial metrics.
  • High-Precision Accuracy: Leverages Fennec Pharmaceuticals Inc.'s (FENC) actual financial data for credible valuation results.
  • Streamlined Scenario Analysis: Easily evaluate various assumptions and analyze different outcomes.
  • Efficiency Booster: Avoid the complexities of constructing detailed valuation models from the ground up.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Fennec Pharmaceuticals Inc.'s (FENC) preloaded data.
  • 2. Modify Assumptions: Adjust critical inputs such as growth rates, WACC, and capital expenditures.
  • 3. View Results in Real-Time: The DCF model automatically computes intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
  • 5. Present with Assurance: Deliver professional valuation insights to back your strategic decisions.

Why Choose This Calculator for Fennec Pharmaceuticals Inc. (FENC)?

  • Accurate Data: Utilize real financial metrics from Fennec Pharmaceuticals for dependable valuation outcomes.
  • Customizable: Tailor critical variables such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations streamline the process, saving you the effort of starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
  • User-Friendly: Designed with an intuitive interface and clear instructions, making it accessible for all users.

Who Should Use This Product?

  • Pharmaceutical Students: Explore drug development processes and apply them to real-world case studies.
  • Researchers: Integrate advanced pharmaceutical models into academic projects or clinical studies.
  • Investors: Evaluate your investment strategies and assess the valuation of Fennec Pharmaceuticals Inc. (FENC).
  • Market Analysts: Enhance your analysis with a customizable model tailored for pharmaceutical valuations.
  • Healthcare Entrepreneurs: Understand how established companies like Fennec Pharmaceuticals Inc. (FENC) navigate the market.

What the Template Contains

  • Pre-Filled Data: Includes Fennec Pharmaceuticals' historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Fennec Pharmaceuticals' profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.